Upcoming Events
  1. ALTG open MAC and SAC meetings

    November 20
  2. Virtual 2020 World Conference on Lung Cancer Singapore

    January 28, 2021 @ 8:00 am - January 31, 2021 @ 5:00 pm

Thoracic oncology highlights from ASCO2020 webinar- recording and evaluation survey

Please fill in the evaluation survey if you have not already done so by clicking on the survey icon at the base of your webinar console.

Please access the recording and evaluation survey here

ALTG awarded $12 million in funding

The ALTG is pleased to announce over $12 million in funding has been successfully awarded to ALTG, NHMRC Clinical Trial Centre and the Australian Genomic Cancer Medicine Centre for the ASPiRATION project. In this ground-breaking precision medicine study, led by ALTG President A/Prof Nick Pavlakis and ALTG Scientific Advisory Committee Chair, Prof Ben Solomon, ASPiRATION will explore the benefit of routine comprehensive genomic profiling in 1000 newly-diagnosed metastatic, non-squamous, NSCLC patients in Australia. The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.

ALTG 14/001 BR.31: A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer – L Seymour (CCTG), S McLachlan (ALTG)

This multicentre, international trial is being coordinated by the Canadian Cancer Trials Group (CCTG; formerly the NCIC Clinical Trials Group). The study opened to recruitment in late July 2015, with a plan to recruit 200 patients across 25 Australian and 1 New Zealand site over a 3 year period.

This study is looking at the impact of adjuvant therapy with MEDI4736 (AstraZeneca, durvalumab) for one year on the disease free survival of patients with early stage (IB >4cm, II or IIIA) NSCLC that is PD-L1 positive. In ANZ, all sites have been activated and 20 patients have been recruited.

State/TerritorySitePIActivation DateRecruitment
ACTCanberra HospitalDavid Leong14 Apr 2016
NSWBorder Medical OncologyCraig Underhill16 Dec 2016
Campbelltown HospitalPo Yee Yip16 Dec 2015
Central Coast Cancer CentreMatthew Chan1 Oct 20151
Chris O'Brien LifehouseSteven Kao11 Dec 20151
Coffs Harbour Health Campus - NCCIKaren Briscoe24 July 2015
Liverpool HospitalVictoria Bray20 Nov 2015
Nepean Cancer Care CentreCatherine Crombine2 Dec 20153
Northern Cancer Institute, St LeonardsNick Pavlakis17 July 20151
St George HospitalChee Lee20 Nov 2015
Westmead HospitalRina Hui17 Jun 2016
QLDMater Adult Hospital BrisbaneFelicity Murphy (mat. leave), Vikram Jain2 Dec 20152
Nambour General HospitalKathleen Houston19 Nov 20151
Princess Alexandra HospitalKen O'Byrne10 Sep 20151
The Prince Charles HospitalBrett Hughes8 Oct 20151
SAFlinders Medical CentreAnand Rose29 July 2016
Royal Adelaide HospitalMichael Brown30 July 20152
TASRoyal Hobart HospitalLouise Nott28 Oct 2015
VICAustin HospitalShane White22 Jan 2016
Epworth Richmond HospitalRoss Jennens22 July 2015
Monash Medical CentrePeter Briggs24 Aug 2016
Peninsula Oncology Centre, FrankstonVinod Ganju2 Mar 2016
Royal Melbourne Hospital, ParkvilleRichard de Boer18 Aug 20151
St Vincent's Hospital Melbourne including St Vincent's Private HospitalSue-Anne McLachlan5 Aug 20153
WAFiona Stanley HospitalAndrew Davidson22 May 2016
Sir Charles Gairdner HospitalMichael Millward8 Oct 20153
Other (NZ)Canterbury Regional Cancer and Haematology ServiceDavid Gibbs19 Nov 2015

Study Contacts

Study Chair: Sue-Anne McLachlan     sue-anne.mcLachlan@svha.org.au

CTC Trial Coordinator: Hannora Jurkovic     BR.31@ctc.usyd.edu.au